Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2025)

Historic Operating Leases for X4 Pharmaceuticals (XFOR) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • X4 Pharmaceuticals' Operating Leases fell 5652.9% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 5652.9%. This contributed to the annual value of $1.4 million for FY2024, which is 4601.84% down from last year.
  • Per X4 Pharmaceuticals' latest filing, its Operating Leases stood at $1.3 million for Q3 2025, which was down 5652.9% from $2.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' Operating Leases' 5-year high stood at $6.5 million during Q1 2021, with a 5-year trough of $1.3 million in Q3 2025.
  • Its 5-year average for Operating Leases is $4.0 million, with a median of $4.0 million in 2023.
  • In the last 5 years, X4 Pharmaceuticals' Operating Leases soared by 16561.84% in 2021 and then crashed by 5652.9% in 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Operating Leases (Quarter) stood at $4.8 million in 2021, then fell by 24.56% to $3.6 million in 2022, then decreased by 27.5% to $2.6 million in 2023, then plummeted by 46.02% to $1.4 million in 2024, then dropped by 8.16% to $1.3 million in 2025.
  • Its Operating Leases stands at $1.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.4 million for Q1 2025.